6 O
ADVERSE O
REACTIONS O
The O
following O
serious O
adverse O
reactions O
are O
discussed O
in O
greater O
detail O
in O
other O
sections O
of O
the O
labeling O
: O
* O
Infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Mucocutaneous B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
* O
Hepatitis B-OSE_Labeled_AE
B I-OSE_Labeled_AE
reactivation I-OSE_Labeled_AE
with O
fulminant B-OSE_Labeled_AE
hepatitis I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
* O
Progressive B-OSE_Labeled_AE
multifocal I-OSE_Labeled_AE
leukoencephalopathy I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
* O
Tumor B-OSE_Labeled_AE
lysis I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
* O
Infections B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
* O
Cardiac B-OSE_Labeled_AE
arrhythmias I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
* O
Renal B-OSE_Labeled_AE
toxicity I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.8 O
) O
] O
* O
Bowel B-OSE_Labeled_AE
obstruction O
and O
perforation I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.9 O
) O
] O
The O
most O
common O
adverse O
reactions O
of O
Rituxan O
( O
incidence O
> O
= O
25 O
% O
) O
observed O
in O
clinical O
trials O
of O
patients O
with O
NHL B-Not_AE_Candidate
were O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
fever B-OSE_Labeled_AE
, O
lymphopenia B-OSE_Labeled_AE
, O
chills B-OSE_Labeled_AE
, O
infection B-OSE_Labeled_AE
, O
and O
asthenia B-OSE_Labeled_AE
. O

The O
most O
common O
adverse O
reactions O
of O
Rituxan O
( O
incidence O
> O
= O
25 O
% O
) O
observed O
in O
clinical O
trials O
of O
patients O
with O
CLL B-Not_AE_Candidate
were O
: O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
and O
neutropenia B-OSE_Labeled_AE
. O

EXCERPT O
: O
Most O
common O
adverse O
reactions O
in O
clinical O
trials O
were O
: O
* O
NHL O
( O
> O
= O
25 O
% O
) O
: O
infusion O
reactions O
, O
fever O
, O
lymphopenia O
, O
chills O
, O
infection O
and O
asthenia O
( O
6.1 O
) O
. O

* O
CLL O
( O
> O
= O
25 O
% O
) O
: O
infusion O
reactions O
and O
neutropenia O
( O
6.1 O
) O
. O

* O
RA O
( O
> O
= O
10 O
% O
) O
: O
upper O
respiratory O
tract O
infection O
, O
nasopharyngitis O
, O
urinary O
tract O
infection O
, O
and O
bronchitis O
( O
other O
important O
adverse O
reactions O
include O
infusion O
reactions O
, O
serious O
infections O
, O
and O
cardiovascular O
events O
) O
( O
6.2 O
) O
. O

* O
GPA O
and O
MPA O
( O
> O
=15 O
% O
) O
: O
infections O
, O
nausea O
, O
diarrhea O
, O
headache O
, O
muscle O
spasms O
, O
anemia O
, O
peripheral O
edema O
( O
other O
important O
adverse O
reactions O
include O
infusion O
reactions O
) O
( O
6.3 O
) O
. O

To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Genentech O
at O
1-888-835-2555 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
in O
Lymphoid O
Malignancies O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
clinical O
practice O
. O

The O
data O
described O
below O
reflect O
exposure O
to O
Rituxan O
in O
2783 O
patients O
, O
with O
exposures O
ranging O
from O
a O
single O
infusion O
up O
to O
2 O
years O
. O

Rituxan O
was O
studied O
in O
both O
single-arm O
and O
controlled O
trials O
( O
n=356 O
and O
n=2427 O
) O
. O

The O
population O
included O
1180 O
patients O
with O
low O
grade O
or O
follicular B-Not_AE_Candidate
lymphoma I-Not_AE_Candidate
, O
927 O
patients O
with O
DLBCL B-Not_AE_Candidate
, O
and O
676 O
patients O
with O
CLL B-Not_AE_Candidate
. O

Most O
NHL B-Not_AE_Candidate
patients O
received O
Rituxan O
as O
an O
infusion O
of O
375 O
mg/m O
2 O
per O
infusion O
, O
given O
as O
a O
single O
agent O
weekly O
for O
up O
to O
8 O
doses O
, O
in O
combination O
with O
chemotherapy O
for O
up O
to O
8 O
doses O
, O
or O
following O
chemotherapy O
for O
up O
to O
16 O
doses O
. O

CLL B-Not_AE_Candidate
patients O
received O
Rituxan O
375 O
mg/m O
2 O
as O
an O
initial O
infusion O
followed O
by O
500 O
mg/m O
2 O
for O
up O
to O
5 O
doses O
, O
in O
combination O
with O
fludarabine O
and O
cyclophosphamide O
. O

Seventy-one O
percent O
of O
CLL B-Not_AE_Candidate
patients O
received O
6 O
cycles O
and O
90 O
% O
received O
at O
least O
3 O
cycles O
of O
Rituxan-based O
therapy O
. O

Infusion O
Reactions O
In O
the O
majority O
of O
patients O
with O
NHL B-Not_AE_Candidate
, O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
consisting O
of O
fever B-NonOSE_AE
, O
chills B-NonOSE_AE
/ O
rigors B-NonOSE_AE
, O
nausea B-NonOSE_AE
, O
pruritus B-NonOSE_AE
, O
angioedema B-NonOSE_AE
, O
hypotension B-NonOSE_AE
, O
headache B-NonOSE_AE
, O
bronchospasm B-NonOSE_AE
, O
urticaria B-NonOSE_AE
, O
rash B-NonOSE_AE
, O
vomiting B-NonOSE_AE
, O
myalgia B-NonOSE_AE
, O
dizziness B-NonOSE_AE
, O
or O
hypertension B-NonOSE_AE
occurred O
during O
the O
first O
Rituxan O
infusion O
. O

Infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
typically O
occurred O
within O
30 O
to O
120 O
minutes O
of O
beginning O
the O
first O
infusion O
and O
resolved O
with O
slowing O
or O
interruption O
of O
the O
Rituxan O
infusion O
and O
with O
supportive O
care O
( O
diphenhydramine O
, O
acetaminophen O
, O
and O
intravenous O
saline O
) O
. O

The O
incidence O
of O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
was O
highest O
during O
the O
first O
infusion O
( O
77 O
% O
) O
and O
decreased O
with O
each O
subsequent O
infusion O
. O

[ O
See O
Boxed O
Warning O
, O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

In O
patients O
with O
previously O
untreated O
follicular O
NHL B-Not_AE_Candidate
or O
previously O
untreated O
DLBCL B-Not_AE_Candidate
, O
who O
did O
not O
experience O
a O
Grade O
3 O
or O
4 O
infusion B-NonOSE_AE
- I-NonOSE_AE
related I-NonOSE_AE
reaction I-NonOSE_AE
in O
Cycle O
1 O
and O
received O
a O
90-minute O
infusion O
of O
Rituxan O
at O
Cycle O
2 O
, O
the O
incidence O
of O
Grade O
3-4 O
infusion B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
on O
the O
day O
of O
, O
or O
day O
after O
the O
infusion O
was O
1.1 O
% O
( O
95 O
% O
CI O
[ O
0.3 O
% O
, O
2.8 O
% O
] O
) O
. O

For O
Cycles O
2-8 O
, O
the O
incidence O
of O
Grade O
3-4 O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
on O
the O
day O
of O
or O
day O
after O
the O
90-minute O
infusion O
, O
was O
2.8 O
% O
( O
95 O
% O
CI O
[ O
1.3 O
% O
, O
5.0 O
% O
] O
) O
. O

[ O
See O
Warnings O
and O
Precautions O
( O
5.1 O
) O
, O
Clinical O
Studies O
( O
14.4 O
) O
] O
. O

Infections O
Serious O
infections B-OSE_Labeled_AE
( O
NCI O
CTCAE O
Grade O
3 O
or O
4 O
) O
, O
including O
sepsis B-OSE_Labeled_AE
, O
occurred O
in O
less O
than O
5 O
% O
of O
patients O
with O
NHL B-Not_AE_Candidate
in O
the O
single-arm O
studies O
. O

The O
overall O
incidence O
of O
infections B-OSE_Labeled_AE
was O
31 O
% O
( O
bacterial I-OSE_Labeled_AE
19 O
% O
, O
viral O
10 O
% O
, O
unknown O
6 O
% O
, O
and O
fungal O
1 O
% O
) O
. O

[ O
See O
Warnings O
and O
Precautions O
( O
5.4 O
) O
, O
( O
5.5 O
) O
, O
( O
5.6 O
) O
] O
. O

In O
randomized O
, O
controlled O
studies O
where O
Rituxan O
was O
administered O
following O
chemotherapy O
for O
the O
treatment O
of O
follicular O
or O
low-grade O
NHL B-Not_AE_Candidate
, O
the O
rate O
of O
infection B-OSE_Labeled_AE
was O
higher O
among O
patients O
who O
received O
Rituxan O
. O

In O
diffuse B-Not_AE_Candidate
large I-Not_AE_Candidate
B I-Not_AE_Candidate
- I-Not_AE_Candidate
cell I-Not_AE_Candidate
lymphoma I-Not_AE_Candidate
patients O
, O
viral B-OSE_Labeled_AE
infections I-OSE_Labeled_AE
occurred O
more O
frequently O
in O
those O
who O
received O
Rituxan O
. O

Cytopenias O
and O
hypogammaglobulinemia O
In O
patients O
with O
NHL B-Not_AE_Candidate
receiving O
rituximab O
monotherapy O
, O
NCI-CTC O
Grade O
3 O
and O
4 O
cytopenias B-OSE_Labeled_AE
were O
reported O
in O
48 O
% O
of O
patients O
. O

These O
included O
lymphopenia B-OSE_Labeled_AE
( O
40 O
% O
) O
, O
neutropenia B-OSE_Labeled_AE
( O
6 O
% O
) O
, O
leukopenia B-OSE_Labeled_AE
( O
4 O
% O
) O
, O
anemia B-OSE_Labeled_AE
( O
3 O
% O
) O
, O
and O
thrombocytopenia B-OSE_Labeled_AE
( O
2 O
% O
) O
. O

The O
median O
duration O
of O
lymphopenia B-OSE_Labeled_AE
was O
14 O
days O
( O
range O
, O
1-588 O
days O
) O
and O
of O
neutropenia B-OSE_Labeled_AE
was O
13 O
days O
( O
range O
, O
2-116 O
days O
) O
. O

A O
single O
occurrence O
of O
transient O
aplastic B-OSE_Labeled_AE
anemia I-OSE_Labeled_AE
( O
pure B-OSE_Labeled_AE
red I-OSE_Labeled_AE
cell I-OSE_Labeled_AE
aplasia I-OSE_Labeled_AE
) O
and O
two O
occurrences O
of O
hemolytic B-OSE_Labeled_AE
anemia I-OSE_Labeled_AE
following O
Rituxan O
therapy O
occurred O
during O
the O
single-arm O
studies O
. O

In O
studies O
of O
monotherapy O
, O
Rituxan-induced O
B B-NonOSE_AE
- I-NonOSE_AE
cell I-NonOSE_AE
depletion I-NonOSE_AE
occurred O
in O
70 O
% O
to O
80 O
% O
of O
patients O
with O
NHL B-Not_AE_Candidate
. O

Decreased B-OSE_Labeled_AE
IgM O
and O
IgG I-OSE_Labeled_AE
serum I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
occurred O
in O
14 O
% O
of O
these O
patients O
. O

In O
CLL B-Not_AE_Candidate
trials O
, O
the O
frequency O
of O
prolonged O
neutropenia B-OSE_Labeled_AE
and O
late-onset O
neutropenia B-OSE_Labeled_AE
was O
higher O
in O
patients O
treated O
with O
R-FC O
compared O
to O
patients O
treated O
with O
FC O
. O

Prolonged O
neutropenia B-NonOSE_AE
is O
defined O
as O
Grade O
3-4 O
neutropenia B-NonOSE_AE
that O
has O
not O
resolved O
between O
24 O
and O
42 O
days O
after O
the O
last O
dose O
of O
study O
treatment O
. O

Late-onset O
neutropenia B-NonOSE_AE
is O
defined O
as O
Grade O
3-4 O
neutropenia B-NonOSE_AE
starting O
at O
least O
42 O
days O
after O
the O
last O
treatment O
dose O
. O

In O
patients O
with O
previously O
untreated O
CLL B-Not_AE_Candidate
, O
the O
frequency O
of O
prolonged O
neutropenia B-OSE_Labeled_AE
was O
8.5 O
% O
for O
patients O
who O
received O
R-FC O
( O
n=402 O
) O
and O
5.8 O
% O
for O
patients O
who O
received O
FC O
( O
n=398 O
) O
. O

In O
patients O
who O
did O
not O
have O
prolonged O
neutropenia B-NonOSE_AE
, O
the O
frequency O
of O
late-onset O
neutropenia B-OSE_Labeled_AE
was O
14.8 O
% O
of O
209 O
patients O
who O
received O
R-FC O
and O
4.3 O
% O
of O
230 O
patients O
who O
received O
FC O
. O

For O
patients O
with O
previously O
treated O
CLL B-Not_AE_Candidate
, O
the O
frequency O
of O
prolonged O
neutropenia B-OSE_Labeled_AE
was O
24.8 O
% O
for O
patients O
who O
received O
R-FC O
( O
n=274 O
) O
and O
19.1 O
% O
for O
patients O
who O
received O
FC O
( O
n=274 O
) O
. O

In O
patients O
who O
did O
not O
have O
prolonged O
neutropenia B-NonOSE_AE
, O
the O
frequency O
of O
late-onset O
neutropenia B-OSE_Labeled_AE
was O
38.7 O
% O
in O
160 O
patients O
who O
received O
R-FC O
and O
13.6 O
% O
of O
147 O
patients O
who O
received O
FC O
. O

Relapsed O
or O
Refractory O
, O
Low-Grade O
NHL O
Adverse O
reactions O
in O
Table O
1 O
occurred O
in O
356 O
patients O
with O
relapsed O
or O
refractory O
, O
low-grade O
or O
follicular O
, O
CD20-positive O
, O
B-cell O
NHL B-Not_AE_Candidate
treated O
in O
single-arm O
studies O
of O
Rituxan O
administered O
as O
a O
single O
agent O
[ O
See O
Clinical O
Studies O
( O
14.1 O
) O
] O
. O

Most O
patients O
received O
Rituxan O
375 O
mg/m O
2 O
weekly O
for O
4 O
doses O
. O

Table O
1 O
Incidence O
of O
Adverse O
Reactions O
in O
> O
= O
5 O
% O
of O
Patients O
with O
Relapsed O
or O
Refractory O
, O
Low-Grade O
or O
Follicular O
NHL O
, O
Receiving O
Single-agent O
Rituxan O
( O
N=356 O
) O
Adverse O
reactions O
observed O
up O
to O
12 O
months O
following O
Rituxan. O
, O
Adverse O
reactions O
graded O
for O
severity O
by O
NCI-CTC O
criteria O
. O

All O
Grades O
( O
% O
) O
Grade O
3 O
and O
4 O
( O
% O
) O
Any O
Adverse O
Reactions O
99 O
57 O
Body B-NonOSE_AE
as I-NonOSE_AE
a I-NonOSE_AE
Whole I-NonOSE_AE
86 O
10 O
Fever B-OSE_Labeled_AE
53 O
1 O
Chills B-OSE_Labeled_AE
33 O
3 O
Infection B-OSE_Labeled_AE
31 O
4 O
Asthenia B-OSE_Labeled_AE
26 O
1 O
Headache B-OSE_Labeled_AE
19 O
1 O
Abdominal B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
14 O
1 O
Pain B-OSE_Labeled_AE
12 O
1 O
Back B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
10 O
1 O
Throat B-OSE_Labeled_AE
Irritation I-OSE_Labeled_AE
9 O
0 O
Flushing B-OSE_Labeled_AE
5 O
0 O
Heme B-NonOSE_AE
and I-NonOSE_AE
Lymphatic I-NonOSE_AE
System I-NonOSE_AE
67 O
48 O
Lymphopenia B-OSE_Labeled_AE
48 O
40 O
Leukopenia B-OSE_Labeled_AE
14 O
4 O
Neutropenia B-OSE_Labeled_AE
14 O
6 O
Thrombocytopenia B-OSE_Labeled_AE
12 O
2 O
Anemia B-OSE_Labeled_AE
8 O
3 O
Skin B-NonOSE_AE
and I-NonOSE_AE
Appendages I-NonOSE_AE
44 O
2 O
Night B-OSE_Labeled_AE
Sweats I-OSE_Labeled_AE
15 O
1 O
Rash B-OSE_Labeled_AE
15 O
1 O
Pruritus B-OSE_Labeled_AE
14 O
1 O
Urticaria B-OSE_Labeled_AE
8 O
1 O
Respiratory B-NonOSE_AE
System I-NonOSE_AE
38 O
4 O
Increased B-OSE_Labeled_AE
Cough I-OSE_Labeled_AE
13 O
1 O
Rhinitis B-OSE_Labeled_AE
12 O
1 O
Bronchospasm B-OSE_Labeled_AE
8 O
1 O
Dyspnea B-OSE_Labeled_AE
7 O
1 O
Sinusitis B-OSE_Labeled_AE
6 O
0 O
Metabolic B-NonOSE_AE
and I-NonOSE_AE
Nutritional I-NonOSE_AE
Disorders I-NonOSE_AE
38 O
3 O
Angioedema B-OSE_Labeled_AE
11 O
1 O
Hyperglycemia B-OSE_Labeled_AE
9 O
1 O
Peripheral B-OSE_Labeled_AE
Edema I-OSE_Labeled_AE
8 O
0 O
LDH B-OSE_Labeled_AE
Increase I-OSE_Labeled_AE
7 O
0 O
Digestive B-NonOSE_AE
System I-NonOSE_AE
37 O
2 O
Nausea B-OSE_Labeled_AE
23 O
1 O
Diarrhea B-OSE_Labeled_AE
10 O
1 O
Vomiting B-OSE_Labeled_AE
10 O
1 O
Nervous B-NonOSE_AE
System I-NonOSE_AE
32 O
1 O
Dizziness B-OSE_Labeled_AE
10 O
1 O
Anxiety B-OSE_Labeled_AE
5 O
1 O
Musculoskeletal B-NonOSE_AE
System I-NonOSE_AE
26 O
3 O
Myalgia B-OSE_Labeled_AE
10 O
1 O
Arthralgia B-OSE_Labeled_AE
10 O
1 O
Cardiovascular B-NonOSE_AE
System I-NonOSE_AE
25 O
3 O
Hypotension B-OSE_Labeled_AE
10 O
1 O
Hypertension B-OSE_Labeled_AE
6 O
1 O
In O
these O
single-arm O
Rituxan O
studies O
, O
bronchiolitis B-OSE_Labeled_AE
obliterans I-OSE_Labeled_AE
occurred O
during O
and O
up O
to O
6 O
months O
after O
Rituxan O
infusion O
. O

Previously O
Untreated O
, O
Low-Grade O
or O
Follicular O
, O
NHL O
In O
Study O
4 O
, O
patients O
in O
the O
R-CVP O
arm O
experienced O
a O
higher O
incidence O
of O
infusional B-OSE_Labeled_AE
toxicity I-OSE_Labeled_AE
and O
neutropenia B-OSE_Labeled_AE
compared O
to O
patients O
in O
the O
CVP O
arm O
. O

The O
following O
adverse O
reactions O
occurred O
more O
frequently O
( O
> O
= O
5 O
% O
) O
in O
patients O
receiving O
R-CVP O
compared O
to O
CVP O
alone O
: O
rash B-OSE_Labeled_AE
( O
17 O
% O
vs O
. O
5 O
% O
) O
, O
cough B-OSE_Labeled_AE
( O
15 O
% O
vs O
. O
6 O
% O
) O
, O
flushing B-OSE_Labeled_AE
( O
14 O
% O
vs O
. O
3 O
% O
) O
, O
rigors B-OSE_Labeled_AE
( O
10 O
% O
vs O
. O
2 O
% O
) O
, O
pruritus B-OSE_Labeled_AE
( O
10 O
% O
vs O
. O
1 O
% O
) O
, O
neutropenia B-OSE_Labeled_AE
( O
8 O
% O
vs O
. O
3 O
% O
) O
, O
and O
chest B-OSE_Labeled_AE
tightness I-OSE_Labeled_AE
( O
7 O
% O
vs O
. O
1 O
% O
) O
. O

[ O
See O
Clinical O
Studies O
( O
14.2 O
) O
] O
. O

In O
Study O
5 O
, O
detailed O
safety O
data O
collection O
was O
limited O
to O
serious O
adverse O
reactions O
, O
Grade O
> O
= O
2 O
infections B-NonOSE_AE
, O
and O
Grade O
> O
= O
3 O
adverse O
reactions O
. O

In O
patients O
receiving O
Rituxan O
as O
single-agent O
maintenance O
therapy O
following O
Rituxan O
plus O
chemotherapy O
, O
infections B-OSE_Labeled_AE
were O
reported O
more O
frequently O
compared O
to O
the O
observation O
arm O
( O
37 O
% O
vs O
. O
22 O
% O
) O
. O

Grade O
3-4 O
adverse O
reactions O
occurring O
at O
a O
higher O
incidence O
( O
> O
= O
2 O
% O
) O
in O
the O
Rituxan O
group O
were O
infections B-OSE_Labeled_AE
( O
4 O
% O
vs O
. O
1 O
% O
) O
and O
neutropenia B-OSE_Labeled_AE
( O
4 O
% O
vs O
. O
< O
1 O
% O
) O
. O

In O
Study O
6 O
, O
the O
following O
adverse O
reactions O
were O
reported O
more O
frequently O
( O
> O
= O
5 O
% O
) O
in O
patients O
receiving O
Rituxan O
following O
CVP O
compared O
to O
patients O
who O
received O
no O
further O
therapy O
: O
fatigue B-OSE_Labeled_AE
( O
39 O
% O
vs O
. O
14 O
% O
) O
, O
anemia B-OSE_Labeled_AE
( O
35 O
% O
vs O
. O
20 O
% O
) O
, O
peripheral B-OSE_Labeled_AE
sensory I-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
( O
30 O
% O
vs O
. O
18 O
% O
) O
, O
infections B-OSE_Labeled_AE
( O
19 O
% O
vs O
. O
9 O
% O
) O
, O
pulmonary B-OSE_Labeled_AE
toxicity I-OSE_Labeled_AE
( O
18 O
% O
vs O
. O
10 O
% O
) O
, O
hepato B-OSE_Labeled_AE
- I-OSE_Labeled_AE
biliary I-OSE_Labeled_AE
toxicity I-OSE_Labeled_AE
( O
17 O
% O
vs O
. O
7 O
% O
) O
, O
rash B-OSE_Labeled_AE
and/or O
pruritus B-OSE_Labeled_AE
( O
17 O
% O
vs O
. O
5 O
% O
) O
, O
arthralgia B-OSE_Labeled_AE
( O
12 O
% O
vs O
. O
3 O
% O
) O
, O
and O
weight B-OSE_Labeled_AE
gain I-OSE_Labeled_AE
( O
11 O
% O
vs O
. O
4 O
% O
) O
. O

Neutropenia B-OSE_Labeled_AE
was O
the O
only O
Grade O
3 O
or O
4 O
adverse O
reaction O
that O
occurred O
more O
frequently O
( O
> O
= O
2 O
% O
) O
in O
the O
Rituxan O
arm O
compared O
with O
those O
who O
received O
no O
further O
therapy O
( O
4 O
% O
vs O
. O
1 O
% O
) O
. O

[ O
See O
Clinical O
Studies O
( O
14.3 O
) O
] O
. O

DLBCL O
In O
Studies O
7 O
and O
8 O
, O
[ O
see O
Clinical O
Studies O
( O
14.3 O
) O
] O
, O
the O
following O
adverse O
reactions O
, O
regardless O
of O
severity O
, O
were O
reported O
more O
frequently O
( O
> O
= O
5 O
% O
) O
in O
patients O
age O
> O
= O
60 O
years O
receiving O
R-CHOP O
as O
compared O
to O
CHOP O
alone O
: O
pyrexia B-OSE_Labeled_AE
( O
56 O
% O
vs O
. O
46 O
% O
) O
, O
lung B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
( O
31 O
% O
vs O
. O
24 O
% O
) O
, O
cardiac B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
( O
29 O
% O
vs O
. O
21 O
% O
) O
, O
and O
chills B-OSE_Labeled_AE
( O
13 O
% O
vs O
. O
4 O
% O
) O
. O

Detailed O
safety O
data O
collection O
in O
these O
studies O
was O
primarily O
limited O
to O
Grade O
3 O
and O
4 O
adverse O
reactions O
and O
serious O
adverse O
reactions O
. O

In O
Study O
8 O
, O
a O
review O
of O
cardiac B-NonOSE_AE
toxicity I-NonOSE_AE
determined O
that O
supraventricular B-OSE_Labeled_AE
arrhythmias I-OSE_Labeled_AE
or O
tachycardia B-OSE_Labeled_AE
accounted O
for O
most O
of O
the O
difference O
in O
cardiac B-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
( O
4.5 O
% O
for O
R-CHOP O
vs O
. O
1.0 O
% O
for O
CHOP O
) O
. O

The O
following O
Grade O
3 O
or O
4 O
adverse O
reactions O
occurred O
more O
frequently O
among O
patients O
in O
the O
R-CHOP O
arm O
compared O
with O
those O
in O
the O
CHOP O
arm O
: O
thrombocytopenia B-OSE_Labeled_AE
( O
9 O
% O
vs O
. O
7 O
% O
) O
and O
lung B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
( O
6 O
% O
vs O
. O
3 O
% O
) O
. O

Other O
Grade O
3 O
or O
4 O
adverse O
reactions O
occurring O
more O
frequently O
among O
patients O
receiving O
R-CHOP O
were O
viral B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
( O
Study O
8 O
) O
, O
neutropenia B-OSE_Labeled_AE
( O
Studies O
8 O
and O
9 O
) O
, O
and O
anemia B-OSE_Labeled_AE
( O
Study O
9 O
) O
. O

CLL O
The O
data O
below O
reflect O
exposure O
to O
Rituxan O
in O
combination O
with O
fludarabine O
and O
cyclophosphamide O
in O
676 O
patients O
with O
CLL B-Not_AE_Candidate
in O
Study O
11 O
or O
Study O
12 O
[ O
See O
Clinical O
Studies O
( O
14.5 O
) O
] O
. O

The O
age O
range O
was O
30-83 O
years O
and O
71 O
% O
were O
men O
. O

Detailed O
safety O
data O
collection O
in O
Study O
11 O
was O
limited O
to O
Grade O
3 O
and O
4 O
adverse O
reactions O
and O
serious O
adverse O
reactions O
. O

Infusion B-NonOSE_AE
- I-NonOSE_AE
related I-NonOSE_AE
adverse I-NonOSE_AE
reactions I-NonOSE_AE
were O
defined O
by O
any O
of O
the O
following O
adverse O
events O
occurring O
during O
or O
within O
24 O
hours O
of O
the O
start O
of O
infusion O
: O
nausea B-NonOSE_AE
, O
pyrexia B-NonOSE_AE
, O
chills B-NonOSE_AE
, O
hypotension B-NonOSE_AE
, O
vomiting B-NonOSE_AE
, O
and O
dyspnea B-NonOSE_AE
. O

In O
Study O
11 O
, O
the O
following O
Grade O
3 O
and O
4 O
adverse O
reactions O
occurred O
more O
frequently O
in O
R-FC-treated O
patients O
compared O
to O
FC-treated O
patients O
: O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
( O
9 O
% O
in O
R-FC O
arm O
) O
, O
neutropenia B-OSE_Labeled_AE
( O
30 O
% O
vs O
. O
19 O
% O
) O
, O
febrile B-OSE_Labeled_AE
neutropenia I-OSE_Labeled_AE
( O
9 O
% O
vs O
. O
6 O
% O
) O
, O
leukopenia B-OSE_Labeled_AE
( O
23 O
% O
vs O
. O
12 O
% O
) O
, O
and O
pancytopenia B-OSE_Labeled_AE
( O
3 O
% O
vs O
. O
1 O
% O
) O
. O

In O
Study O
12 O
, O
the O
following O
Grade O
3 O
or O
4 O
adverse O
reactions O
occurred O
more O
frequently O
in O
R-FC-treated O
patients O
compared O
to O
FC-treated O
patients O
: O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
( O
7 O
% O
in O
R-FC O
arm O
) O
, O
neutropenia B-OSE_Labeled_AE
( O
49 O
% O
vs O
. O
44 O
% O
) O
, O
febrile B-OSE_Labeled_AE
neutropenia I-OSE_Labeled_AE
( O
15 O
% O
vs O
. O
12 O
% O
) O
, O
thrombocytopenia B-OSE_Labeled_AE
( O
11 O
% O
vs O
. O
9 O
% O
) O
, O
hypotension B-OSE_Labeled_AE
( O
2 O
% O
vs O
. O
0 O
% O
) O
, O
and O
hepatitis B-OSE_Labeled_AE
B I-OSE_Labeled_AE
( O
2 O
% O
vs O
. O
< O
1 O
% O
) O
. O

Fifty-nine O
percent O
of O
R-FC-treated O
patients O
experienced O
an O
infusion B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
of O
any O
severity O
. O

6.2 O
Clinical O
Trials O
Experience O
in O
Rheumatoid O
Arthritis O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

The O
data O
presented O
below O
reflect O
the O
experience O
in O
2578 O
RA B-Not_AE_Candidate
patients O
treated O
with O
Rituxan O
in O
controlled O
and O
long-term O
studies O
with O
a O
total O
exposure O
of O
5014 O
patient-years O
. O

Among O
all O
exposed O
patients O
, O
adverse O
reactions O
reported O
in O
greater O
than O
10 O
% O
of O
patients O
include O
infusion B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
nasopharyngitis B-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
and O
bronchitis B-OSE_Labeled_AE
. O

In O
placebo-controlled O
studies O
, O
patients O
received O
2 O
* O
500 O
mg O
or O
2 O
* O
1000 O
mg O
intravenous O
infusions O
of O
Rituxan O
or O
placebo O
, O
in O
combination O
with O
methotrexate O
, O
during O
a O
24-week O
period O
. O

From O
these O
studies O
, O
938 O
patients O
treated O
with O
Rituxan O
( O
2 O
* O
1000 O
mg O
) O
or O
placebo O
have O
been O
pooled O
( O
see O
Table O
2 O
) O
. O

Adverse O
reactions O
reported O
in O
> O
= O
5 O
% O
of O
patients O
were O
hypertension B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
arthralgia B-OSE_Labeled_AE
, O
pyrexia B-OSE_Labeled_AE
and O
pruritus B-OSE_Labeled_AE
( O
see O
Table O
2 O
) O
. O

The O
rates O
and O
types O
of O
adverse O
reactions O
in O
patients O
who O
received O
Rituxan O
2 O
* O
500 O
mg O
were O
similar O
to O
those O
observed O
in O
patients O
who O
received O
Rituxan O
2 O
* O
1000 O
mg O
. O
Table O
2These O
data O
are O
based O
on O
938 O
patients O
treated O
in O
Phase O
2 O
and O
3 O
studies O
of O
Rituxan O
( O
2 O
* O
1000 O
mg O
) O
or O
placebo O
administered O
in O
combination O
with O
methotrexate O
. O

Incidence O
of O
All O
Adverse O
ReactionsCoded O
using O
MedDRA O
. O

Occurring O
in O
> O
= O
2 O
% O
and O
at O
Least O
1 O
% O
Greater O
than O
Placebo O
Among O
Rheumatoid O
Arthritis O
Patients O
in O
Clinical O
Studies O
Up O
to O
Week O
24 O
( O
Pooled O
) O
Preferred O
Term O
Placebo O
+ O
MTXN=398n O
( O
% O
) O
Rituxan O
+ O
MTXN=540n O
( O
% O
) O
Hypertension B-OSE_Labeled_AE
21 O
( O
5 O
) O
43 O
( O
8 O
) O
Nausea B-OSE_Labeled_AE
19 O
( O
5 O
) O
41 O
( O
8 O
) O
Upper B-OSE_Labeled_AE
Respiratory I-OSE_Labeled_AE
Tract I-OSE_Labeled_AE
Infection I-OSE_Labeled_AE
23 O
( O
6 O
) O
37 O
( O
7 O
) O
Arthralgia B-OSE_Labeled_AE
14 O
( O
4 O
) O
31 O
( O
6 O
) O
Pyrexia B-OSE_Labeled_AE
8 O
( O
2 O
) O
27 O
( O
5 O
) O
Pruritus B-OSE_Labeled_AE
5 O
( O
1 O
) O
26 O
( O
5 O
) O
Chills B-OSE_Labeled_AE
9 O
( O
2 O
) O
16 O
( O
3 O
) O
Dyspepsia B-OSE_Labeled_AE
3 O
( O
< O
1 O
) O
16 O
( O
3 O
) O
Rhinitis B-OSE_Labeled_AE
6 O
( O
2 O
) O
14 O
( O
3 O
) O
Paresthesia B-OSE_Labeled_AE
3 O
( O
< O
1 O
) O
12 O
( O
2 O
) O
Urticaria B-OSE_Labeled_AE
3 O
( O
< O
1 O
) O
12 O
( O
2 O
) O
Abdominal B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
Upper I-OSE_Labeled_AE
4 O
( O
1 O
) O
11 O
( O
2 O
) O
Throat B-OSE_Labeled_AE
Irritation I-OSE_Labeled_AE
0 O
( O
0 O
) O
11 O
( O
2 O
) O
Anxiety B-OSE_Labeled_AE
5 O
( O
1 O
) O
9 O
( O
2 O
) O
Migraine B-OSE_Labeled_AE
2 O
( O
< O
1 O
) O
9 O
( O
2 O
) O
Asthenia B-OSE_Labeled_AE
1 O
( O
< O
1 O
) O
9 O
( O
2 O
) O
Infusion O
Reactions O
In O
the O
Rituxan O
RA B-Not_AE_Candidate
pooled O
placebo-controlled O
studies O
, O
32 O
% O
of O
Rituxan-treated O
patients O
experienced O
an O
adverse O
reaction O
during O
or O
within O
24 O
hours O
following O
their O
first O
infusion O
, O
compared O
to O
23 O
% O
of O
placebo-treated O
patients O
receiving O
their O
first O
infusion O
. O

The O
incidence O
of O
adverse O
reactions O
during O
the O
24-hour O
period O
following O
the O
second O
infusion O
, O
Rituxan O
or O
placebo O
, O
decreased O
to O
11 O
% O
and O
13 O
% O
, O
respectively O
. O

Acute O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
( O
manifested O
by O
fever B-NonOSE_AE
, O
chills B-NonOSE_AE
, O
rigors B-NonOSE_AE
, O
pruritus B-NonOSE_AE
, O
urticaria B-NonOSE_AE
/ O
rash B-NonOSE_AE
, O
angioedema B-NonOSE_AE
, O
sneezing B-NonOSE_AE
, O
throat B-NonOSE_AE
irritation I-NonOSE_AE
, O
cough B-NonOSE_AE
, O
and/or O
bronchospasm B-NonOSE_AE
, O
with O
or O
without O
associated O
hypotension B-NonOSE_AE
or O
hypertension B-NonOSE_AE
) O
were O
experienced O
by O
27 O
% O
of O
Rituxan-treated O
patients O
following O
their O
first O
infusion O
, O
compared O
to O
19 O
% O
of O
placebo-treated O
patients O
receiving O
their O
first O
placebo O
infusion O
. O

The O
incidence O
of O
these O
acute O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
following O
the O
second O
infusion O
of O
Rituxan O
or O
placebo O
decreased O
to O
9 O
% O
and O
11 O
% O
, O
respectively O
. O

Serious O
acute O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
were O
experienced O
by O
< O
1 O
% O
of O
patients O
in O
either O
treatment O
group O
. O

Acute O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
required O
dose O
modification O
( O
stopping O
, O
slowing O
, O
or O
interruption O
of O
the O
infusion O
) O
in O
10 O
% O
and O
2 O
% O
of O
patients O
receiving O
rituximab O
or O
placebo O
, O
respectively O
, O
after O
the O
first O
course O
. O

The O
proportion O
of O
patients O
experiencing O
acute O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
decreased O
with O
subsequent O
courses O
of O
Rituxan O
. O

The O
administration O
of O
intravenous O
glucocorticoids O
prior O
to O
Rituxan O
infusions O
reduced O
the O
incidence O
and O
severity O
of O
such O
reactions O
, O
however O
, O
there O
was O
no O
clear O
benefit O
from O
the O
administration O
of O
oral O
glucocorticoids O
for O
the O
prevention O
of O
acute O
infusion B-NonOSE_AE
reactions I-NonOSE_AE
. O

Patients O
in O
clinical O
studies O
also O
received O
antihistamines O
and O
acetaminophen O
prior O
to O
Rituxan O
infusions O
. O

Infections O
In O
the O
pooled O
, O
placebo-controlled O
studies O
, O
39 O
% O
of O
patients O
in O
the O
Rituxan O
group O
experienced O
an O
infection B-OSE_Labeled_AE
of O
any O
type O
compared O
to O
34 O
% O
of O
patients O
in O
the O
placebo O
group O
. O

The O
most O
common O
infections B-OSE_Labeled_AE
were O
nasopharyngitis B-OSE_Labeled_AE
, O
upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
, O
bronchitis B-OSE_Labeled_AE
, O
and O
sinusitis B-OSE_Labeled_AE
. O

The O
incidence O
of O
serious O
infections B-OSE_Labeled_AE
was O
2 O
% O
in O
the O
Rituxan-treated O
patients O
and O
1 O
% O
in O
the O
placebo O
group O
. O

In O
the O
experience O
with O
Rituxan O
in O
2578 O
RA B-Not_AE_Candidate
patients O
, O
the O
rate O
of O
serious O
infections B-OSE_Labeled_AE
was O
4.31 O
per O
100 O
patient O
years O
. O

The O
most O
common O
serious O
infections B-OSE_Labeled_AE
( O
> O
= O
0.5 O
% O
) O
were O
pneumonia B-OSE_Labeled_AE
or O
lower B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
, O
cellulitis B-OSE_Labeled_AE
and O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
. O

Fatal B-NonOSE_AE
serious O
infections B-OSE_Labeled_AE
included O
pneumonia B-OSE_Labeled_AE
, O
sepsis B-OSE_Labeled_AE
and O
colitis B-OSE_Labeled_AE
. O

Rates O
of O
serious O
infection B-NonOSE_AE
remained O
stable O
in O
patients O
receiving O
subsequent O
courses O
. O

In O
185 O
Rituxan-treated O
RA B-Not_AE_Candidate
patients O
with O
active O
disease O
, O
subsequent O
treatment O
with O
a O
biologic O
DMARD O
, O
the O
majority O
of O
which O
were O
TNF O
antagonists O
, O
did O
not O
appear O
to O
increase O
the O
rate O
of O
serious O
infection B-NonOSE_AE
. O

Thirteen O
serious O
infections B-OSE_Labeled_AE
were O
observed O
in O
186.1 O
patient O
years O
( O
6.99 O
per O
100 O
patient O
years O
) O
prior O
to O
exposure O
and O
10 O
were O
observed O
in O
182.3 O
patient O
years O
( O
5.49 O
per O
100 O
patient O
years O
) O
after O
exposure O
. O

Cardiac O
Adverse O
Reactions O
In O
the O
pooled O
, O
placebo-controlled O
studies O
, O
the O
proportion O
of O
patients O
with O
serious O
cardiovascular B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
was O
1.7 O
% O
and O
1.3 O
% O
in O
the O
Rituxan O
and O
placebo O
treatment O
groups O
, O
respectively O
. O

Three O
cardiovascular O
deaths B-NonOSE_AE
occurred O
during O
the O
double-blind O
period O
of O
the O
RA B-Not_AE_Candidate
studies O
including O
all O
rituximab O
regimens O
( O
3/769 O
= O
0.4 O
% O
) O
as O
compared O
to O
none O
in O
the O
placebo O
treatment O
group O
( O
0/389 O
) O
. O

In O
the O
experience O
with O
Rituxan O
in O
2578 O
RA B-Not_AE_Candidate
patients O
, O
the O
rate O
of O
serious O
cardiac B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
was O
1.93 O
per O
100 O
patient O
years O
. O

The O
rate O
of O
myocardial B-OSE_Labeled_AE
infarction I-OSE_Labeled_AE
( I-OSE_Labeled_AE
MI I-OSE_Labeled_AE
) O
was O
0.56 O
per O
100 O
patient O
years O
( O
28 O
events O
in O
26 O
patients O
) O
, O
which O
is O
consistent O
with O
MI B-NonOSE_AE
rates O
in O
the O
general O
RA B-Not_AE_Candidate
population O
. O

These O
rates O
did O
not O
increase O
over O
three O
courses O
of O
Rituxan O
. O

Since O
patients O
with O
RA B-Not_AE_Candidate
are O
at O
increased O
risk O
for O
cardiovascular B-NonOSE_AE
events I-NonOSE_AE
compared O
with O
the O
general O
population O
, O
patients O
with O
RA B-Not_AE_Candidate
should O
be O
monitored O
throughout O
the O
infusion O
and O
Rituxan O
should O
be O
discontinued O
in O
the O
event O
of O
a O
serious O
or O
life-threatening O
cardiac B-NonOSE_AE
event I-NonOSE_AE
. O

Hypophosphatemia O
and O
hyperuricemia O
In O
the O
pooled O
, O
placebo-controlled O
studies O
, O
newly-occurring O
hypophosphatemia B-OSE_Labeled_AE
( O
< O
2.0 O
mg/dl O
) O
was O
observed O
in O
12 O
% O
( O
67/540 O
) O
of O
patients O
on O
Rituxan O
versus O
10 O
% O
( O
39/398 O
) O
of O
patients O
on O
placebo O
. O

Hypophosphatemia B-OSE_Labeled_AE
was O
more O
common O
in O
patients O
who O
received O
corticosteroids O
. O

Newly-occurring O
hyperuricemia B-OSE_Labeled_AE
( O
> O
10 O
mg/dl O
) O
was O
observed O
in O
1.5 O
% O
( O
8/540 O
) O
of O
patients O
on O
Rituxan O
versus O
0.3 O
% O
( O
1/398 O
) O
of O
patients O
on O
placebo O
. O

In O
the O
experience O
with O
Rituxan O
in O
RA B-Not_AE_Candidate
patients O
, O
newly-occurring O
hypophosphatemia B-OSE_Labeled_AE
was O
observed O
in O
21 O
% O
( O
528/2570 O
) O
of O
patients O
and O
newly-occurring O
hyperuricemia B-OSE_Labeled_AE
was O
observed O
in O
2 O
% O
( O
56/2570 O
) O
of O
patients O
. O

The O
majority O
of O
the O
observed O
hypophosphatemia B-OSE_Labeled_AE
occurred O
at O
the O
time O
of O
the O
infusions O
and O
was O
transient O
. O

Retreatment O
in O
Patients O
with O
RA O
In O
the O
experience O
with O
Rituxan O
in O
RA B-Not_AE_Candidate
patients O
, O
2578 O
patients O
have O
been O
exposed O
to O
Rituxan O
and O
have O
received O
up O
to O
10 O
courses O
of O
Rituxan O
in O
RA B-Not_AE_Candidate
clinical O
trials O
, O
with O
1890 O
, O
1043 O
, O
and O
425 O
patients O
having O
received O
at O
least O
two O
, O
three O
, O
and O
four O
courses O
, O
respectively O
. O

Most O
of O
the O
patients O
who O
received O
additional O
courses O
did O
so O
24 O
weeks O
or O
more O
after O
the O
previous O
course O
and O
none O
were O
retreated O
sooner O
than O
16 O
weeks O
. O

The O
rates O
and O
types O
of O
adverse O
reactions O
reported O
for O
subsequent O
courses O
of O
Rituxan O
were O
similar O
to O
rates O
and O
types O
seen O
for O
a O
single O
course O
of O
Rituxan O
. O

In O
RA O
Study O
2 O
, O
where O
all O
patients O
initially O
received O
Rituxan O
, O
the O
safety O
profile O
of O
patients O
who O
were O
retreated O
with O
Rituxan O
was O
similar O
to O
those O
who O
were O
retreated O
with O
placebo O
[ O
See O
Clinical O
Studies O
( O
14.6 O
) O
, O
and O
Dosage O
and O
Administration O
( O
2.5 O
) O
] O
. O

6.3 O
Clinical O
Trials O
Experience O
in O
Granulomatosis O
with O
Polyangiitis O
( O
GPA O
) O
( O
Wegener O
's O
Granulomatosis O
) O
and O
Microscopic O
Polyangiitis O
( O
MPA O
) O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

The O
data O
presented O
below O
reflect O
the O
experience O
in O
197 O
patients O
with O
GPA B-Not_AE_Candidate
and O
MPA B-Not_AE_Candidate
treated O
with O
Rituxan O
or O
cyclophosphamide O
in O
a O
single O
controlled O
study O
, O
which O
was O
conducted O
in O
two O
phases O
: O
a O
6 O
month O
randomized O
, O
double-blind O
, O
double-dummy O
, O
active-controlled O
remission O
induction O
phase O
and O
an O
additional O
12 O
month O
remission O
maintenance O
phase O
. O

In O
the O
6-month O
remission O
induction O
phase O
, O
197 O
patients O
with O
GPA B-Not_AE_Candidate
and O
MPA B-Not_AE_Candidate
were O
randomized O
to O
either O
Rituxan O
375 O
mg/ O
m O
2 O
once O
weekly O
for O
4 O
weeks O
plus O
glucocorticoids O
, O
or O
oral O
cyclophosphamide O
2 O
mg/kg O
daily O
( O
adjusted O
for O
renal O
function O
, O
white O
blood O
cell O
count O
, O
and O
other O
factors O
) O
plus O
glucocorticoids O
to O
induce O
remission O
. O

Once O
remission O
was O
achieved O
or O
at O
the O
end O
of O
the O
6 O
month O
remission O
induction O
period O
, O
the O
cyclophosphamide O
group O
received O
azathioprine O
to O
maintain O
remission O
. O

The O
Rituxan O
group O
did O
not O
receive O
additional O
therapy O
to O
maintain O
remission O
. O

The O
primary O
analysis O
was O
at O
the O
end O
of O
the O
6 O
month O
remission O
induction O
period O
and O
the O
safety O
results O
for O
this O
period O
are O
described O
below O
. O

Adverse O
reactions O
presented O
below O
in O
Table O
3 O
were O
adverse O
events O
which O
occurred O
at O
a O
rate O
of O
greater O
than O
or O
equal O
to O
10 O
% O
in O
the O
Rituxan O
group O
. O

This O
table O
reflects O
experience O
in O
99 O
GPA O
and O
MPA B-Not_AE_Candidate
patients O
treated O
with O
Rituxan O
, O
with O
a O
total O
of O
47.6 O
patient-years O
of O
observation O
and O
98 O
GPA B-Not_AE_Candidate
and O
MPA B-Not_AE_Candidate
patients O
treated O
with O
cyclophosphamide O
, O
with O
a O
total O
of O
47.0 O
patient-years O
of O
observation O
. O

Infection B-OSE_Labeled_AE
was O
the O
most O
common O
category O
of O
adverse O
events O
reported O
( O
47-62 O
% O
) O
and O
is O
discussed O
below O
. O

Table O
3 O
Incidence O
of O
All O
Adverse O
Reactions O
Occurring O
in O
> O
= O
10 O
% O
of O
Rituxan-treated O
GPA O
and O
MPA O
Patients O
in O
the O
Clinical O
Study O
Up O
to O
Month O
6The O
study O
design O
allowed O
for O
crossover O
or O
treatment O
by O
best O
medical O
judgment O
, O
and O
13 O
patients O
in O
each O
treatment O
group O
received O
a O
second O
therapy O
during O
the O
6 O
month O
study O
period O
. O

Preferred O
Term O
RituxanN=99n O
( O
% O
) O
CyclophosphamideN=98n O
( O
% O
) O
Nausea B-OSE_Labeled_AE
18 O
( O
18 O
% O
) O
20 O
( O
20 O
% O
) O
Diarrhea B-OSE_Labeled_AE
17 O
( O
17 O
% O
) O
12 O
( O
12 O
% O
) O
Headache B-OSE_Labeled_AE
17 O
( O
17 O
% O
) O
19 O
( O
19 O
% O
) O
Muscle B-OSE_Labeled_AE
spasms I-OSE_Labeled_AE
17 O
( O
17 O
% O
) O
15 O
( O
15 O
% O
) O
Anemia B-OSE_Labeled_AE
16 O
( O
16 O
% O
) O
20 O
( O
20 O
% O
) O
Peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
16 O
( O
16 O
% O
) O
6 O
( O
6 O
% O
) O
Insomnia B-OSE_Labeled_AE
14 O
( O
14 O
% O
) O
12 O
( O
12 O
% O
) O
Arthralgia B-OSE_Labeled_AE
13 O
( O
13 O
% O
) O
9 O
( O
9 O
% O
) O
Cough B-OSE_Labeled_AE
13 O
( O
13 O
% O
) O
11 O
( O
11 O
% O
) O
Fatigue B-OSE_Labeled_AE
13 O
( O
13 O
% O
) O
21 O
( O
21 O
% O
) O
Increased B-OSE_Labeled_AE
ALT I-OSE_Labeled_AE
13 O
( O
13 O
% O
) O
15 O
( O
15 O
% O
) O
Hypertension B-OSE_Labeled_AE
12 O
( O
12 O
% O
) O
5 O
( O
5 O
% O
) O
Epistaxis B-OSE_Labeled_AE
11 O
( O
11 O
% O
) O
6 O
( O
6 O
% O
) O
Dyspnea B-OSE_Labeled_AE
10 O
( O
10 O
% O
) O
11 O
( O
11 O
% O
) O
Leukopenia B-OSE_Labeled_AE
10 O
( O
10 O
% O
) O
26 O
( O
27 O
% O
) O
Rash B-OSE_Labeled_AE
10 O
( O
10 O
% O
) O
17 O
( O
17 O
% O
) O
Infusion O
Reactions O
Infusion B-NonOSE_AE
- I-NonOSE_AE
related I-NonOSE_AE
reactions I-NonOSE_AE
in O
the O
active-controlled O
, O
double-blind O
study O
were O
defined O
as O
any O
adverse O
event O
occurring O
within O
24 O
hours O
of O
an O
infusion O
and O
considered O
to O
be O
infusion-related O
by O
investigators O
. O

Among O
the O
99 O
patients O
treated O
with O
Rituxan O
, O
12 O
% O
experienced O
at O
least O
one O
infusion B-OSE_Labeled_AE
related I-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
, O
compared O
with O
11 O
% O
of O
the O
98 O
patients O
in O
the O
cyclophosphamide O
group O
. O

Infusion B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
included O
cytokine B-OSE_Labeled_AE
release I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
flushing B-OSE_Labeled_AE
, O
throat B-OSE_Labeled_AE
irritation I-OSE_Labeled_AE
, O
and O
tremor B-OSE_Labeled_AE
. O

In O
the O
Rituxan O
group O
, O
the O
proportion O
of O
patients O
experiencing O
an O
infusion B-OSE_Labeled_AE
related I-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
was O
12 O
% O
, O
5 O
% O
, O
4 O
% O
, O
and O
1 O
% O
following O
the O
first O
, O
second O
, O
third O
, O
and O
fourth O
infusions O
, O
respectively O
. O

Patients O
were O
pre-medicated O
with O
antihistamine O
and O
acetaminophen O
before O
each O
Rituxan O
infusion O
and O
were O
on O
background O
oral O
corticosteroids O
which O
may O
have O
mitigated O
or O
masked O
an O
infusion B-NonOSE_AE
reaction I-NonOSE_AE
; O
however O
, O
there O
is O
insufficient O
evidence O
to O
determine O
whether O
premedication O
diminishes O
the O
frequency O
or O
severity O
of O
infusion B-NonOSE_AE
reactions I-NonOSE_AE
. O

Infections O
In O
the O
active-controlled O
, O
double-blind O
study O
, O
62 O
% O
( O
61/99 O
) O
of O
patients O
in O
the O
Rituxan O
group O
experienced O
an O
infection B-OSE_Labeled_AE
of O
any O
type O
compared O
to O
47 O
% O
( O
46/98 O
) O
patients O
in O
the O
cyclophosphamide O
group O
by O
Month O
6 O
. O

The O
most O
common O
infections B-OSE_Labeled_AE
in O
the O
Rituxan O
group O
were O
upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
, O
and O
herpes B-OSE_Labeled_AE
zoster I-OSE_Labeled_AE
. O

The O
incidence O
of O
serious O
infections B-OSE_Labeled_AE
was O
11 O
% O
in O
the O
Rituxan-treated O
patients O
and O
10 O
% O
in O
the O
cyclophosphamide O
treated O
patients O
, O
with O
rates O
of O
approximately O
25 O
and O
28 O
per O
100 O
patient-years O
, O
respectively O
. O

The O
most O
common O
serious O
infection O
was O
pneumonia B-OSE_Labeled_AE
. O

Hypogammaglobulinemia O
Hypogammaglobulinemia B-OSE_Labeled_AE
( O
IgA B-OSE_Labeled_AE
, O
IgG O
or O
IgM O
below I-OSE_Labeled_AE
the I-OSE_Labeled_AE
lower I-OSE_Labeled_AE
limit I-OSE_Labeled_AE
of I-OSE_Labeled_AE
normal I-OSE_Labeled_AE
) O
has O
been O
observed O
in O
patients O
with O
GPA B-Not_AE_Candidate
and O
MPA B-Not_AE_Candidate
treated O
with O
Rituxan O
. O

At O
6 O
months O
, O
in O
the O
Rituxan O
group O
, O
27 O
% O
, O
58 O
% O
and O
51 O
% O
of O
patients O
with O
normal O
immunoglobulin O
levels O
at O
baseline O
, O
had O
low B-OSE_Labeled_AE
IgA I-OSE_Labeled_AE
, O
IgG O
and O
IgM O
levels O
, O
respectively O
compared O
to O
25 O
% O
, O
50 O
% O
and O
46 O
% O
in O
the O
cyclophosphamide O
group O
. O

Retreatment O
in O
Patients O
with O
GPA O
and O
MPA O
In O
the O
active-controlled O
, O
double-blind O
study O
, O
subsequent O
courses O
of O
Rituxan O
were O
allowed O
for O
patients O
experiencing O
a O
relapse O
of O
disease O
. O

The O
limited O
data O
preclude O
any O
conclusions O
regarding O
the O
safety O
of O
subsequent O
courses O
of O
Rituxan O
with O
GPA B-Not_AE_Candidate
and O
MPA B-Not_AE_Candidate
[ O
See O
Dosage O
and O
Administration O
( O
2.6 O
) O
, O
and O
Warnings O
and O
Precautions O
( O
5.14 O
) O
] O
. O

6.4 O
Immunogenicity O
As O
with O
all O
therapeutic O
proteins O
, O
there O
is O
a O
potential O
for O
immunogenicity B-OSE_Labeled_AE
. O

The O
observed O
incidence O
of O
antibody B-NonOSE_AE
( O
including O
neutralizing O
a O
ntibody B-NonOSE_AE
) I-NonOSE_AE
positivity I-NonOSE_AE
  I-NonOSE_AE
I-NonOSE_AE O
in O
an O
assay O
is O
highly O
dependent O
on O
several O
factors O
including O
assay O
sensitivity O
and O
specificity O
, O
assay O
methodology O
, O
sample O
handling O
, O
timing O
of O
sample O
collection O
, O
concomitant O
medications O
, O
and O
underlying O
disease O
. O

For O
these O
reasons O
, O
comparison O
of O
the O
incidence O
of O
antibodies B-NonOSE_AE
to I-NonOSE_AE
Rituxan I-NonOSE_AE
with O
the O
incidence O
of O
antibodies B-NonOSE_AE
to I-NonOSE_AE
other I-NonOSE_AE
products I-NonOSE_AE
may O
be O
misleading O
. O

Using O
an O
ELISA O
assay O
, O
anti B-OSE_Labeled_AE
- I-OSE_Labeled_AE
human I-OSE_Labeled_AE
anti I-OSE_Labeled_AE
- I-OSE_Labeled_AE
chimeric I-OSE_Labeled_AE
antibody I-OSE_Labeled_AE
( I-OSE_Labeled_AE
HACA I-OSE_Labeled_AE
) O
was O
detected O
in O
4 O
of O
356 O
( O
1.1 O
% O
) O
patients O
with O
low-grade O
or O
follicular O
NHL B-Not_AE_Candidate
receiving O
single-agent O
Rituxan O
. O

Three O
of O
the O
four O
patients O
had O
an O
objective O
clinical O
response O
. O

A O
total O
of O
273/2578 O
( O
11 O
% O
) O
patients O
with O
RA B-Not_AE_Candidate
tested O
positive B-OSE_Labeled_AE
for I-OSE_Labeled_AE
HACA I-OSE_Labeled_AE
at O
any O
time O
after O
receiving O
Rituxan O
. O

HACA B-NonOSE_AE
positivity O
was O
not O
associated O
with O
increased O
infusion B-NonOSE_AE
reactions I-NonOSE_AE
or O
other O
adverse O
reactions O
. O

Upon O
further O
treatment O
, O
the O
proportions O
of O
patients O
with O
infusion B-NonOSE_AE
reactions I-NonOSE_AE
were O
similar O
between O
HACA B-NonOSE_AE
positive I-NonOSE_AE
and O
negative O
patients O
, O
and O
most O
reactions O
were O
mild O
to O
moderate O
. O

Four O
HACA B-OSE_Labeled_AE
positive I-OSE_Labeled_AE
patients O
had O
serious O
infusion B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
and O
the O
temporal O
relationship O
between O
HACA B-NonOSE_AE
positivity I-NonOSE_AE
and O
infusion B-NonOSE_AE
reaction I-NonOSE_AE
was O
variable O
. O

A O
total O
of O
23/99 O
( O
23 O
% O
) O
Rituxan-treated O
patients O
with O
GPA B-Not_AE_Candidate
and O
MPA B-Not_AE_Candidate
tested O
positive B-OSE_Labeled_AE
for I-OSE_Labeled_AE
HACA I-OSE_Labeled_AE
by O
18 O
months O
. O

The O
clinical O
relevance O
of O
HACA B-NonOSE_AE
formation I-NonOSE_AE
in O
Rituxan-treated O
patients O
is O
unclear O
. O

6.5 O
Postmarketing O
Experience O
Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

Decisions O
to O
include O
these O
reactions O
in O
labeling O
are O
typically O
based O
on O
one O
or O
more O
of O
the O
following O
factors O
: O
( O
1 O
) O
seriousness O
of O
the O
reaction O
, O
( O
2 O
) O
frequency O
of O
reporting O
, O
or O
( O
3 O
) O
strength O
of O
causal O
connection O
to O
Rituxan O
. O

* O
Hematologic B-NonOSE_AE
: O
prolonged O
pancytopenia B-OSE_Labeled_AE
, O
marrow B-OSE_Labeled_AE
hypoplasia I-OSE_Labeled_AE
, O
Grade O
3-4 O
prolonged O
or O
late-onset O
neutropenia B-OSE_Labeled_AE
, O
hyperviscosity B-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
in I-OSE_Labeled_AE
Waldenstrom I-OSE_Labeled_AE
' I-OSE_Labeled_AE
s I-OSE_Labeled_AE
macroglobulinemia I-OSE_Labeled_AE
, O
prolonged O
hypogammaglobulinemia B-OSE_Labeled_AE
[ O
See O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
. O

* O
Cardiac B-NonOSE_AE
: O
fatal B-NonOSE_AE
cardiac B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
. O

* O
Immune B-NonOSE_AE
/ I-NonOSE_AE
Autoimmune I-NonOSE_AE
Events I-NonOSE_AE
: O
uveitis B-OSE_Labeled_AE
, O
optic B-OSE_Labeled_AE
neuritis I-OSE_Labeled_AE
, O
systemic B-OSE_Labeled_AE
vasculitis I-OSE_Labeled_AE
, O
pleuritis B-OSE_Labeled_AE
, O
lupus B-OSE_Labeled_AE
- I-OSE_Labeled_AE
like I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
serum B-OSE_Labeled_AE
sickness I-OSE_Labeled_AE
, O
polyarticular B-OSE_Labeled_AE
arthritis I-OSE_Labeled_AE
, O
and O
vasculitis B-OSE_Labeled_AE
with O
rash B-OSE_Labeled_AE
. O

* O
Infection B-NonOSE_AE
: O
viral B-OSE_Labeled_AE
infections I-OSE_Labeled_AE
, O
including O
progressive B-OSE_Labeled_AE
multifocal I-OSE_Labeled_AE
leukoencephalopathy I-OSE_Labeled_AE
( I-OSE_Labeled_AE
PML I-OSE_Labeled_AE
) O
, O
increase O
in O
fatal B-NonOSE_AE
infections B-OSE_Labeled_AE
in O
HIV B-Not_AE_Candidate
- I-Not_AE_Candidate
associated I-Not_AE_Candidate
lymphoma I-Not_AE_Candidate
, O
and O
a O
reported O
increased O
incidence O
of O
Grade O
3 O
and O
4 O
infections B-OSE_Labeled_AE
[ O
See O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
. O

* O
Neoplasia B-NonOSE_AE
: O
disease B-OSE_Labeled_AE
progression I-OSE_Labeled_AE
of I-OSE_Labeled_AE
Kaposi I-OSE_Labeled_AE
' I-OSE_Labeled_AE
s I-OSE_Labeled_AE
sarcoma I-OSE_Labeled_AE
. O

* O
Skin B-NonOSE_AE
: O
severe O
mucocutaneous B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
. O

* O
Gastrointestinal B-NonOSE_AE
: O
bowel B-OSE_Labeled_AE
obstruction I-OSE_Labeled_AE
and O
perforation O
. O

* O
Pulmonary B-NonOSE_AE
: O
fatal B-NonOSE_AE
bronchiolitis B-OSE_Labeled_AE
obliterans I-OSE_Labeled_AE
and O
fatal B-NonOSE_AE
interstitial B-OSE_Labeled_AE
lung I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
. O

* O
Nervous B-NonOSE_AE
system I-NonOSE_AE
: O
Posterior B-OSE_Labeled_AE
Reversible I-OSE_Labeled_AE
Encephalopathy I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
( I-OSE_Labeled_AE
PRES I-OSE_Labeled_AE
) O
/ O
Reversible B-OSE_Labeled_AE
Posterior I-OSE_Labeled_AE
Leukoencephalopathy I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
( I-OSE_Labeled_AE
RPLS I-OSE_Labeled_AE
) O
. O

